Published in Surgery Litigation and Law Weekly, May 11th, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at Boston Scientific Corporation.
Report 1: Boston Scientific Corporation (NYSE:BSX) announced two-year results from the TAXUS V In-Stent Restenosis (ISR) trial, demonstrating that the TAXUS(R) Express2(TM) paclitaxel-eluting coronary stent system met its primary endpoint in the treatment of in-stent restenosis - the regrowth of diseased tissue into a previously stented artery utilizing bare-metal stents - compared to vascular brachytherapy. The Company made the announcement at...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Surgery Litigation and Law Weekly